You are here: Industry Insights > cell and gene therapy

News List

CCRM and Amgen Partner to Advance Emerging Medical Innovations contractpharma
May 06, 2021
New regenerative medicine discoveries, including cell and gene therapies, will never reach patients without access to the funding, expertise and other specialized support that are required to move along the commercialization pathway.
PPD to Expand GMP Lab in Ireland contractpharma
April 30, 2021
PPD, Inc., a global contract research organization (CRO), is expanding its Athlone, Ireland, GMP laboratory, increasing the size of its current facility and adding cell and gene therapy testing to the operation’s portfolio of services.
Catalent Adds Cryogenic Capabilities at Philadelphia Facility contractpharma
April 16, 2021
Bolsters clinical supply services at site to meet growing demand for cell and gene therapy development.
BioCentriq, Kytopen Enter Cell Therapy Alliance contractpharma
March 25, 2021
BioCentriq, the New Jersey Innovation Institute’s cell and gene therapy development and manufacturing center, is partnering with Kytopen, a Cambridge-based startup spun out of Massachusetts Institute of Technology (MIT).
BioCentriq and Kytopen Enter Cell Therapy Partnership contractpharma
March 24, 2021
BioCentriq, the New Jersey Innovation Institute’s cell and gene therapy development and manufacturing center, has entered a partnership with Kytopen, a Cambridge, MA-based startup spun out of Massachusetts Institute of Technology (MIT).
Tevogen Bio, BioCentriq Partner for COVID T-cell Therapy contractpharma
March 17, 2021
Tevogen Bio has entered a partnership with BioCentriq, a New Jersey based cell and gene therapy development and manufacturing center, to support clinical manufacturing of Tevogen’s investigational COVID-19 treatment.
LabConnect Expands Johnson City Facility contractpharma
March 17, 2021
LabConnect, a global provider of central laboratory and support services for the biopharmaceutical industry, finalized plans to add 20,000 sq.-ft. at its Johnson City facility.
GSK to leverage the Cell and Gene Therapy Catapult’s facility in Stevenage pharmatimes
March 12, 2021
GlaxoSmithKline (GSK) is set to leverage the Cell and Gene Therapy (CGT) Catapult’s facility in Stevenage to expand its own clinical trial manufacturing capacity for cell and gene therapy.
AGC Biologics Announces the Expansion of Their Cell and Gene Therapy Facility in Milan, Italy prnasia
March 04, 2021
AGC Biologics announced plans for the expansion of their Cell and Gene Therapy Center of Excellence in Milan, to increase capacities and implement viral vector suspension capabilities.
Rentschler Biopharma to build cell and gene therapy manufacturing capabilities in the UK pharmatimes
February 24, 2021
Rentschler Biopharma, a German contract development and manufacturing organisation (CDMO), will build new cell and gene therapy capabilities at a Cell and Gene Therapy (CGT) Catapult site in Stevenage, UK.

Previous page 1 2 3 4 5 Next page